Allurion Technologies’ gastric balloon+GLP1s may become new SOC, says Roth MKM
Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo.
Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment
Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.
Allurion announces initial results from Allurion Program-GLP-1 combo
Allurion Technologies (ALUR) announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize ...
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose ...
Le Lézard13h
Neogen Announces Third-Quarter Earnings Release Date
Neogen® Corporation will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. Executives from the company will host a webcast and conference call ...
Le Lézard13h
Danaher Schedules First Quarter 2025 Earnings Conference Call
Danaher Corporation announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one ...
Yahoo Finance23d
Allurion to Participate in Upcoming Investor Conferences
NATICK, Mass., February 25, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity ...
Nasdaq3d
ALLURION TECHNOLOGIES Earnings Preview: Recent $ALUR Insider Trading, Hedge Fund Activity, and More
ALLURION TECHNOLOGIES ($ALUR) is expected to release its quarterly earnings data on Wednesday, March 19th before market open, per Finnhub. Analysts are expecting ...
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and ...
Business Wire28d
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...
Business Wire23d
Allurion to Participate in Upcoming Investor Conferences
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...
Roth Capital Has Pessimistic Outlook of ALUR Q1 Earnings
Research analysts at Roth Capital dropped their Q1 2025 EPS estimates for Allurion Technologies in a research note issued to investors on Wednesday, March 5th. Roth Capital analyst J. Wittes now ...